← All indications
Arthritis, Psoriatic
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
Drugs by status
Approved for this indication (20)
Phase 4 trials (14)
Phase 3 trials (15)
Phase 2 trials (21)
Phase 1 trials (14)
Organizations
Organization Involved with Phase 4 Indications (30)
- AbbVie
- Amgen
- Centocor
- Eli Lilly
- Pfizer
- Wyeth
- Novartis
- Kyowa Hakko Kirin
- Mallinckrodt
- Medical University of Graz
- Harvard University
- Diakonhjemmet Hospital
- Medical University Innsbruck
- Michigan State University
- University of Rochester
- University of South Florida
- Chinese University of Hong Kong
- University of Copenhagen
- Medical University of Vienna
- J. Dietl Hospital, Krakow
- University of Oxford
- University of Erlangen-Nuremberg
- Jagiellonian University
- Humboldt University
- National Institute for Health Research, United Kingdom
- South-Eastern Norway Regional Health Authority
- Iris Pharma
- The Danish Rheumatism Association
- The Cleveland Clinic
- The Danish Psoriasis Association
Organization Involved with Phase 3 Indications (41)
- Bristol-Myers Squibb
- Galapagos NV
- Bausch Health Companies
- Gilead Sciences
- Merck Serono
- Mylan
- Biocad
- Sun Pharmaceuticals
- Ajou University
- Dong-A University
- Gachon University
- Hanyang University
- Hoosier Cancer Research Network
- Instituto de Medicina Molecular
- Korea University
- Kyung Hee University
- Seoul National University
- University of Leeds
- Yonsei University
- Chonbuk National University
- Daegu Catholic University
- Bangladesh Medical University
- University of Amsterdam
- Chungnam National University
- Jikei University
- Konkuk University
- Catholic University of Korea
- Mitsubishi Tanabe
- Eulji University
- Janssen Pharmaceutica NV
- +11 more
Organization Involved with Phase 2 Indications (39)
- AltruBio
- Astellas
- Novo Nordisk
- Biogen
- AmpliPhi Biosciences Corporation
- Boehringer Ingelheim
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Brown University
- University of London
- Hasselt University
- Katholieke Universiteit Leuven
- Lund University
- Newcastle University
- Oregon Health and Science University
- Radboud University
- Stanford University
- University of Hamburg
- University of Heidelberg
- University of Liverpool
- University of Manchester
- University of Toronto
- University of Leipzig
- Aalborg University
- University of Cambridge
- University of Chicago
- Leiden University
- CHU Brugmann
- Free University of Berlin
- Alder Biopharmaceuticals
- +9 more
Organization Involved with Phase 1 Indications (18)
- PPD
- Fresenius
- Roche
- Sandoz
- Genentech
- Biothera
- GlaxoSmithKline
- Parexel
- PanGenetics UK Limited
- Xoma
- University of Washington
- Comac Medical
- Novum Pharmaceutical Research Services
- Pharmaceutical Research Associates, Inc. (PRA)
- MAC Clinical Research
- Institute of Rheumatology, Belgrade, Serbia
- Seattle Rheumatology Associates/ Swedish Research Center
- ARENSIA, Moldova
Organization Involved with Other Experimental Indications (3)